View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 9, 2019

Daiichi Sankyo receives Japanese marketing approval for two drugs

Daiichi Sankyo has obtained marketing approval in Japan for its minnebro and tarlige tablets to treat hypertension and peripheral neuropathic pain (PNP) respectively.

Daiichi Sankyo has obtained marketing approval in Japan for its minnebro and tarlige tablets to treat hypertension and peripheral neuropathic pain (PNP) respectively.

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

Minnebro was identified during a partnership with US-based drug discovery company Exelixis and was then developed by Daiichi Sankyo.

The approval is based on data from Phase III clinical studies, including ESAX-HTN trial that compared the safety and efficacy of the drug with eplerenone in Japanese essential hypertension patients.

Minnebro is being further evaluated by Daiichi Sankyo in a separate Phase III trial involving patients suffering from diabetic nephropathy in Japan.

“We are committed to using resulting collaboration revenues to reinvest in our business, build our pipeline, and pursue long-term, sustainable growth.”

The collaboration will see with Daiichi Sankyo pay Exelixis $20m in milestone payment upon the first commercial sale of the drug in Japan.

Exelixis president and CEO Michael Morrissey said: “The approval of minnebro brings an important new therapeutic option to clinicians in Japan.

“As partnered compounds like Minnebro are commercialised, we are committed to using resulting collaboration revenues to reinvest in our business, build our pipeline, and pursue long-term, sustainable growth.”

The approval granted for tarlige comes after a review of data from a Phase III trial in diabetic peripheral neuropathic pain (DPNP) patients and another study in subjects with postherpetic neuralgia (PHN).

Tarlige is an Alpha2delta ligand that binds to the respective subunits of voltage-dependent calcium channels.

Daiichi Sankyo and UCB Japan have received approval for the expanded indication of vimpat tablets. This adds a new dosage and administration regimen for paediatric epilepsy patients with partial onset seizures with or without secondary generalisation.

Related Companies

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology